Investment
Features
FeesSafety
Academy
More
Pluang+

Bitcoin could hit $500,000 by 2030, says adviser Ric Edelman, comparing it to Amazon's early growth phase.

Market News
18 Sep 2026
Zycrypto
View Source
Bullish
Bitcoin could hit $500,000 by 2030, says adviser Ric Edelman, comparing it to Amazon's early growth phase.

Financial adviser Ric Edelman forecasts Bitcoin could reach $500,000 by 2030, likening its current stage to Amazon in 1999 when it was still gaining investor trust. Edelman bases this on the assumption that global investors might allocate about 1% of their portfolios to Bitcoin as adoption grows. Currently trading around $76,633, Bitcoin would need to increase over 550% to meet this target. Edelman views this forecast as conservative compared to other predictions and highlights Bitcoin's potential to become a mainstream investment asset over time.

Bitcoin price is currently around $76,633 as of Sep 18, 2026 19:01 WIB, providing context for Ric Edelman's prediction of $500,000 by 2030. For readers following cryptocurrency markets, here is Pluang's market snapshot as of Sep 18, 2026 19:01 WIB: out of 50 major cryptocurrencies priced on Pluang, 46 rose and 3 fell today. Notable movers include AAVE at Rp2.387.385 with a 9.57% increase and 86% buy order activity, GRT at Rp348 with a 9.03% increase, and XTZ at Rp4.773 with an 8.85% increase and 98% buy order activity.

More News

Duke Energy's stock shows 8.26% upside with strong earnings forecast and mixed institutional interest.

Duke Energy's stock shows 8.26% upside with strong earnings forecast and mixed institutional interest.

Duke Energy Corporation's stock is projected to rise about 8.26% to a price target of $127, down slightly from $133, reflecting confidence despite a recent price dip. The company expects a 4.42% increase in earnings per share to $1.89 and a 3.86% ris...

Analyst Insights
Bullish
24 minutes ago
Xenon Pharmaceuticals stock plunges 27.6% after pausing clinical trials due to safety concerns.

Xenon Pharmaceuticals stock plunges 27.6% after pausing clinical trials due to safety concerns.

Xenon Pharmaceuticals halted new patient enrollment in its psychiatry clinical trials for the drug azetukalner after reports of neuropsychiatric side effects. This pause led to a sharp 27.6% drop in its stock price, marking its worst day since 2017. ...

Market News
Bearish
1 hour ago
Innate Pharma beats EPS estimates and secures $75M deal with Sobi, boosting cash runway to 2028

Innate Pharma beats EPS estimates and secures $75M deal with Sobi, boosting cash runway to 2028

Innate Pharma reported an EPS of -$0.24, beating analyst estimates of -$0.29, and revenue of $6.5 million, slightly above expectations. The company secured a strategic partnership with Sobi for its drug lacutamab, receiving a $75 million upfront paym...

Company Fundamentals
Bullish
1 hour ago
Paychex to report Q1 2027 earnings with expected EPS of $1.32 and $1.63B revenue on Sept 23

Paychex to report Q1 2027 earnings with expected EPS of $1.32 and $1.63B revenue on Sept 23

Paychex, a provider of human capital management solutions, will release its Q1 fiscal 2027 earnings on September 23, 2026. Analysts expect earnings per share (EPS) of $1.32, up from $1.22 last year, and revenue of about $1.63 billion, higher than las...

Company Fundamentals
Bullish
2 hours ago
Barclays cuts Lennar price target to $70 amid weak Q3 earnings and housing market challenges

Barclays cuts Lennar price target to $70 amid weak Q3 earnings and housing market challenges

Barclays lowered its price target for Lennar Corporation to $70 from a higher level, citing a 52% drop in Q3 net earnings to $284 million and an 8.6% revenue decline to $8.05 billion. The homebuilder faces headwinds from rising mortgage rates and wea...

Analyst Insights
Bearish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App